$Efficacy and Safety of Dual-targeted Chimeric Antigen Receptor-T Cell Therapy in Patients with Refractory-relapsed Multiple Myeloma: a Meta-analysis$

Efficacy and Safety of Dual-targeted Chimeric Antigen Receptor-T Cell Therapy in Patients with Refractory-relapsed Multiple Myeloma: a Meta-analysis

Background Chimeric antigen receptor (CAR) -T cell immunotherapy has achieved good therapeutic effect in multiple myeloma (MM) , and the most common target is B cell maturation antigen (BCMA) . The disadvantage of single target CAR-T cell immunotherapy is that it can lead to disease resistance and r...

Full description

Bibliographic Details
Main Author:	YU Haibo, ZHANG Tianyu, LI Xin, ZHANG Jiajia, SHEN Man, ZHAN Xiaokai, TANG Ran, FAN Sibin, ZHAO Fengyi, HUANG Zhongxia
Format:	Article
Language:	zho
Published:	Chinese General Practice Publishing House Co., Ltd 2024-03-01
Series:	Zhongguo quanke yixue
Subjects:	multiple myeloma\|refractory-relapsed multiple myelomachimeric\|antigen receptor t-cell immunotherapy\|meta-analysis
Online Access:	https://www.chinagp.net/fileup/1007-9572/PDF/20230454.pdf

Similar Items

How I treat relapsed and/or refractory multiple myeloma
by: Hans C. Lee, et al.
Published: (2020-09-01)

Carfilzomib for relapsed and refractory multiple myeloma
by: Groen K, et al.
Published: (2019-04-01)

Bendamustine in patients with relapsed or refractory multiple myeloma
by: Michael M, et al.
Published: (2010-01-01)

A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
by: Wan-Hong Zhao, et al.
Published: (2018-12-01)

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
by: Francesca Fazio, et al.
Published: (2022-02-01)

Phase II trial of daratumumab with DCEP in relapsed/refractory multiple myeloma patients with extramedullary disease
by: Ja Min Byun, et al.
Published: (2022-10-01)

Clinical Outcomes Related to the Use of Bendamustine Therapy for Multiple Myeloma Patients Relapsed/Refractory to Immunomodulatory Drugs and Proteasome Inhibitors
by: Fevzi Fırat Yalnız, et al.
Published: (2017-08-01)

The molecular mechanism and challenge of targeting XPO1 in treatment of relapsed and refractory myeloma
by: Mark Sellin, et al.
Published: (2022-08-01)

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma
by: Felipe de Arriba de la Fuente, et al.
Published: (2022-12-01)

Progression-Free Survival Efficacy in Refractory/Relapsed Multiple Myeloma among Elderly Patients: A Systematic Review
by: Tung-Lung Yang, et al.
Published: (2023-11-01)

Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
by: Bhutani D, et al.
Published: (2017-07-01)

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments
by: Massimo Offidani, et al.
Published: (2021-02-01)

Carfilzomib Based Treatment Strategies in the Management of Relapsed/Refractory Multiple Myeloma with Extramedullary Disease
by: Xiang Zhou, et al.
Published: (2020-04-01)

Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review
by: Abubakar Tauseef, et al.
Published: (2022-01-01)

Management of Adverse Events and Supportive Therapy in Relapsed/Refractory Multiple Myeloma
by: Samantha Pozzi, et al.
Published: (2021-10-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Impact of glucocorticoids on short-term and long-term outcomes in patients with relapsed/refractory multiple myeloma treated with CAR-T therapy
by: Xue Wang, et al.
Published: (2022-08-01)

Single-Cell Transcriptomes Combining with Consecutive Genomics Reveal Clonal Evolution and Gene Regulatory Networks in Relapsed and Refractory Multiple Myeloma
by: Jiadai Xu, et al.
Published: (2022-01-01)

Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma: Results of the Compassionate Use or the Expanded Access Program in Spain
by: Javier de la Rubia, et al.
Published: (2023-05-01)

Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye
by: Atakan Tekinalp, et al.
Published: (2023-12-01)

Pomalidomide and Dexamethasone Are Effective in Relapsed or Refractory Multiple Myeloma in a Real-Life Setting: A Multicenter Retrospective Study in Taiwan
by: Yu-Chin Hung, et al.
Published: (2021-05-01)

Daratumumab triplet therapies in patients with relapsed or refractory multiple myeloma: A “real world” experience
by: Ludovica Fucci, et al.
Published: (2022-01-01)

Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy
by: Lei Qiu, et al.
Published: (2020-06-01)

Advances in the Treatment of Relapsed and Refractory Multiple Myeloma in Patients with Renal Insufficiency: Novel Agents, Immunotherapies and Beyond
by: Boris Bozic, et al.
Published: (2021-10-01)

Bendamustine-Based Regimens as Salvage Therapy in Refractory/Relapsed Multiple Myeloma Patients: A Retrospective Real-Life Analysis by the Polish Myeloma Group
by: Norbert Grzasko, et al.
Published: (2021-11-01)

The Role of Bispecific Antibodies in Relapsed Refractory Multiple Myeloma: A Systematic Review
by: Razwana Khanam, et al.
Published: (2023-05-01)

Mezigdomide—A Novel Cereblon E3 Ligase Modulator under Investigation in Relapsed/Refractory Multiple Myeloma
by: Monique A. Hartley-Brown, et al.
Published: (2024-03-01)

Pomalidomide for the management of relapsed and refractory multiple myeloma: a case report and review of literature
by: S. V. Semochkin
Published: (2015-10-01)

A combination of pre-infusion serum ferritin, CRP and IL-6 predicts outcome in relapsed/refractory multiple myeloma patients treated with CAR-T cells
by: Yang Liu, et al.
Published: (2023-04-01)

Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe
by: Evangelos Terpos, et al.
Published: (2022-10-01)

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma
by: Cong Xu, et al.
Published: (2021-05-01)

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model
by: Niels vanNieuwenhuijzen, et al.
Published: (2024-02-01)

Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database
by: Arleigh McCurdy, et al.
Published: (2022-03-01)

Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
by: Lugui Qiu, et al.
Published: (2022-04-01)

Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease
by: Haobin Deng, et al.
Published: (2021-08-01)

Sequential CD19 and BCMA‐specific CAR T‐cell treatment elicits sustained remission of relapsed and/or refractory myeloma
by: Lingzhi Yan, et al.
Published: (2021-01-01)

Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
by: Luca Cancanelli, et al.
Published: (2023-01-01)

Efficacy of ixazomib-lenalidomide-dexamethasone in high-molecular-risk relapsed/refractory multiple myeloma – case series and literature review
by: Aneta Szudy-Szczyrek, et al.
Published: (2021-06-01)

Treatment options for refractory/relapsed multiple myeloma: an updated evidence synthesis by network meta-analysis
by: Luo XW, et al.
Published: (2018-08-01)